Dengue Fever News and Research

RSS
Dengue (DF) and dengue hemorrhagic fever (DHF) are caused by one of four closely related, but antigenically distinct, virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), of the genus Flavivirus. Infection with one of these serotypes provides immunity to only that serotype for life, so persons living in a dengue-endemic area can have more than one dengue infection during their lifetime. DF and DHF are primarily diseases of tropical and sub tropical areas, and the four different dengue serotypes are maintained in a cycle that involves humans and the Aedes mosquito. However, Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans, is the most common Aedes species. Infections produce a spectrum of clinical illness ranging from a nonspecific viral syndrome to severe and fatal hemorrhagic disease. Important risk factors for DHF include the strain of the infecting virus, as well as the age, and especially the prior dengue infection history of the patient.
BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

Cost of dengue vaccine production could be as low as $0.20 per dose

Cost of dengue vaccine production could be as low as $0.20 per dose

FDA approves test for dengue virus infection

FDA approves test for dengue virus infection

FDA approves CDC DENV-1-4 Real Time RT PCR Assay to treat dengue

FDA approves CDC DENV-1-4 Real Time RT PCR Assay to treat dengue

Transgenic mosquitoes can control malaria

Transgenic mosquitoes can control malaria

Magazine examines efforts to biologically alter bugs to fight human diseases

Magazine examines efforts to biologically alter bugs to fight human diseases

Dengue fever vaccine 'may be in sight,' Reuters reports

Dengue fever vaccine 'may be in sight,' Reuters reports

Neighborhood immunity has a role in determining risk of dengue infection

Neighborhood immunity has a role in determining risk of dengue infection

New insights into how body's innate immunity is triggered to create effective immune response

New insights into how body's innate immunity is triggered to create effective immune response

Dengue fever costs Puerto Rico nearly $38M a year, study shows

Dengue fever costs Puerto Rico nearly $38M a year, study shows

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

Europe becoming 'hotspot' for emerging infections, study suggests

Europe becoming 'hotspot' for emerging infections, study suggests

Gates Foundation, Brazilian health ministry form alliance to expand Grand Challenges in Global Health initiative

Gates Foundation, Brazilian health ministry form alliance to expand Grand Challenges in Global Health initiative

Sri Lankan health officials report increase in number of dengue cases in first quarter compared to 2011

Sri Lankan health officials report increase in number of dengue cases in first quarter compared to 2011

PloS ONE publishes research on GenVec's new vaccine vectors

PloS ONE publishes research on GenVec's new vaccine vectors

Dengue infection makes mosquito's blood feeding more efficient

Dengue infection makes mosquito's blood feeding more efficient

Infection with dengue virus turns on feeding-related genes in mosquitoes

Infection with dengue virus turns on feeding-related genes in mosquitoes

GenVec announces data from respiratory syncytial virus vaccine program

GenVec announces data from respiratory syncytial virus vaccine program